Cigna Group
NYSE: CI·Bloomfield, Connecticut·CIK 0001739940
- Price
- $300.16
- Base IV
- $621.21
Valuation snapshot
At $300.16, the price is below even our bear case of $392.85.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $621.21
- above today's price · range $392.85–$929.66
- Price vs base case
- 52% below
- $300.16 against $621.21
- Base case · our researched forecast, 2026-11-06See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $392.85 to bull $929.66. Values per share.
Price against each value
- Bear case
- $392.85
- Price 24% below
- No growth
- …
- —
- Base case
- $621.21
- Price 52% below
What does Cigna Group do?
The Cigna Group provides pharmacy benefit management, medical insurance, and coordinated healthcare services to help employers and individuals manage healthcare costs and access medical care.
It brought in $286.3B of sales in the 12 months to Sep 2026.
Led by Brian Evanko, President and Chief Executive Officer since 2026. Brian Evanko | The Cigna Group Leadership
- Industry
- Financials
- Based in
- Bloomfield, Connecticut
- Trades on
- NYSE as CI
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 2¢ was left as profit after every cost, interest and tax. The biggest cost is everything else it takes to operate, 92¢ of every dollar.
- Sales, marketing and admin5¢
- Everything else it takes to operate92¢
- Tax1¢
- Left as profit2¢
Who pays Cigna Group, and for what?
The Cigna Group sells pharmacy, medical, behavioral, dental and related health services. It earns revenue from pharmacy services and drug sales, health insurance premiums, and fees for administering health plans and other services.
Its customers and clients include individuals, employers, unions, insurers, benefit administrators, health care providers and government health programs.
Evernorth Health Services
Pharmacy benefit services, specialty pharmacy and drug distribution, virtual care, benefits management and other care services.
Cigna Healthcare
U.S. and international medical plans and related health benefits and services for employers, groups and individuals.
Other Operations
Corporate-owned life insurance, run-off businesses and other non-strategic operations.
Where its work physically happens, beyond headquarters:
- Evernorth Health Services HQ (One Express Way) — St. Louis, United States. This leased campus, at and around One Express Way, is the corporate office for Evernorth Health Services, which includes Express Scripts PBM, Accredo specialty pharmacy and CuraScript distribution, and the 10-K lists it among Cigna's principal domestic offices.
- Two Liberty Place offices — Philadelphia, United States. Leased office space at Two Liberty Place in Philadelphia is one of Cigna's three principal domestic offices, which together total about 1.8 million square feet, and it supports the Cigna Healthcare benefits operations.
- Express Scripts Pharmacy automated home-delivery pharmacy (Indiana) — Whitestown, United States. The 10-K says Express Scripts runs one of its four high-volume automated dispensing pharmacies in Indiana; the federal NPI registry places its mail-order pharmacy at 4750 E 450 S, Whitestown, and this capacity fills the mail-order prescriptions behind Evernorth's pharmacy revenue.
- Express Scripts Pharmacy automated home-delivery pharmacy (Arizona) — Tempe, United States. The 10-K says one of Express Scripts' four high-volume automated dispensing pharmacies is in Arizona, and directory listings put its pharmacy at 7909 S Hardy Dr in Tempe; this site gives the West Coast mail-order fulfillment network a second location for backup and volume.
How is the business doing?
Sales grew from $160.4B in 2020 to $274.9B in 2025, about 11% a year.
Running the business leaves about 3¢ of each sales dollar as operating profit, about the same as 5¢ in 2020.
What does management say it's aiming for?
Cigna says it aims to improve the health and vitality of the people and communities it serves.
“improve the health and vitality of those we serve”
Who is responsible for the plan?
- Brian EvankoPresident and Chief Executive Officer
Brian Evanko oversees The Cigna Group's global healthcare operations, enterprise strategy, and primary growth platforms, Cigna Healthcare and Evernorth Health Services. The Cigna Group generates revenue primarily through pharmacy benefit services, specialty pharmacy operations, and commercial and government healthcare premiums and administrative fees.
- Bryan HolgersonPresident, Cigna Healthcare U.S. and Executive Vice President, Customer Health Outcomes
Bryan Holgerson oversees Cigna Healthcare's U.S. commercial businesses, including employer and individual health plans, as well as enterprise customer health outcomes. Cigna Healthcare generates revenue through commercial health insurance premiums and administrative fees charged for insured and self-funded medical benefit plans.
- Durga Prasad (DP) KokaExecutive Vice President and Global Chief Information Officer
Durga Prasad Koka leads the Technology and Operations organization, overseeing global infrastructure, cybersecurity, application development, and operational platforms across the enterprise. The company's digital architecture and core technology platforms process pharmacy claims, support benefits administration, and deliver services to healthcare clients and members.
Roles checked November 14, 2026.
What management says it is working on now:
Make pharmacy benefits more transparent
The company plans to make drug discounts available upfront to customers, with the stated aim of lowering costs at the counter.
The Cigna Group 2025 Form 10-KImprove the health care experience
Its Commitments to Better focus on easier access, more support, better value, accountability and transparency for customers and patients.
The Cigna Group 2025 Form 10-KImprove operating efficiency
The company says its multiyear strategic optimization program is intended to improve efficiency and the experience for patients, providers and customers.
The Cigna Group 2025 Form 10-KExpand digital and data capabilities
Management describes a digital-first approach, using data and technology to personalize services, improve operations and help identify health needs.
The Cigna Group 2025 Form 10-KSupport affordable, coordinated care
The company focuses on combining pharmacy and medical services, managing drug costs and working with care providers to improve affordability and outcomes.
The Cigna Group 2025 Form 10-K
- Annualized after-tax savings from strategic optimization program, Not specified
- At least $500 million
- The Cigna Group 2025 Form 10-K
What's changing right now?
Growth is slowing. In Q3 2026 it sold 6% more than a year earlier. The year before, quarters averaged 8%.
Its operating margin is about where it was a year ago, 3¢ per sales dollar.
Since Oct 2026 the share price has fallen 1%, from $304.37 to $300.16.
Recently
December 31, 2025
Annual Capital Expenditures changed to $1.2B
The Cigna Group 2025 Form 10-K Statement of Cash FlowsDecember 31, 2025
Evernorth Pharmacy Customers (Year-End) changed to 123600000 number
The Cigna Group Q4 2025 Earnings ReleaseDecember 31, 2025
Cigna Healthcare Medical Care Ratio (MCR), full-year changed to 84.4%
The Cigna Group 2025 Form 10-K Item 7
Coming up
Beginning in 2027
Cigna Healthcare adopts the upfront-discount pharmacy model
Cigna Healthcare plans to use the new pharmacy benefits model for its fully insured customers.
The Cigna Group 2025 Form 10-KBeginning in 2028
New model becomes standard for Evernorth clients
The upfront-discount pharmacy benefits model is expected to become the standard model available to Evernorth pharmacy benefit clients.
The Cigna Group 2025 Form 10-KEffective beginning August 2028
New employer plan rebate remittance rules take effect
The law requires pharmacy benefit managers to remit certain rebates, fees and other payments to employer plan sponsors, and adds disclosure and reporting requirements.
The Cigna Group 2025 Form 10-KEffective January 2029
Medicare Part D pharmacy contract rules change
The law requires Part D plan sponsors to contract with pharmacies that can meet standard contract terms and conditions.
The Cigna Group 2025 Form 10-K
Our own estimate moved too: the base case went from $667.42 to $621.21 a share between our last two valuations. The biggest reason: Cigna Healthcare Medical Care Ratio (MCR), full-year moved from an unreported prior value to 84.4%, as reported in The Cigna Group 2025 Form 10-K Item 7.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Health care costs may exceed estimates
The company sets many prices before it knows the actual cost of care. If medical costs or service use are higher than expected, premiums or fees may not cover its costs.
From the company's own filingsWould hit how much of each sale it keepsThe Cigna Group 2025 Form 10-K
Clients may switch providers or demand lower prices
Employers and other clients can seek competing bids and move their business. Losing a major client or accepting less favorable contract terms could hurt revenue and profits.
From the company's own filingsWould hit how fast sales growThe Cigna Group 2025 Form 10-K
New rules could change pharmacy benefit services
Laws and regulations may change how pharmacy benefit managers handle rebates, report compensation or contract with pharmacies. The company says the eventual effects of recently enacted provisions are not yet clear.
From the company's own filingsWould hit how much of each sale it keepsThe Cigna Group 2025 Form 10-K
Pharmacy pricing and competition may pressure margins
Clients are seeking lower prices and a greater share of drug rebates. If the company cannot adapt its services and rebate-free model, it could have trouble keeping clients or protecting margins.
From the company's own filingsWould hit how much of each sale it keepsThe Cigna Group 2025 Form 10-K
Dependence on a large pharmacy benefit client
One pharmacy benefit client accounted for about 19% of 2025 revenue. Losing that client or renegotiating its contract on worse terms could materially affect results.
From the company's own filingsWould hit how fast sales growThe Cigna Group 2025 Form 10-K
Sensitive data and systems could be compromised
The company handles personal health and financial information and depends on technology for services such as pharmacy claims processing. A security or system failure could disrupt operations and damage trust.
From the company's own filingsWould hit how fast sales growThe Cigna Group 2025 Form 10-K
Full year 2025 revenue grew 11.24% to $274.9 billion, significantly outpacing the forward 5% expectation.
From our researchWould hit how fast sales growThe Cigna Group 2025 Form 10-K
Investments in digital health platforms and biosimilar distribution facilities occasionally require multi-hundred million dollar capital outlays.
From our researchWould hit how much it has to reinvestThe Cigna Group Investor Day Transcripts
Is it a good business?
From 2018 to 2025 it earned between 4% and 11% on the capital invested in it, a median of 9%. Its cost of capital in the latest valuation is 6.4%; returns were above it in 7 of the 8 years.
From 2018 to 2025 it earned between 6% and 17% on its shareholders' equity, a median of 11%.
Over 8 years its operating margin ranged from 3¢ to 9¢ per sales dollar, a median of 5¢. Gross margin ran from 22¢ to 90¢.
Cost of capital 6.4%
It bought back shares: the count fell 1.4% in a year, so each remaining share owns a slightly bigger slice.
It owes $25B more than it holds in cash, about 2.6 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $300.16. Our put its value between $392.85 and $929.66, with $621.21 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $392.85
This scenario envisions a difficult road ahead where revenue growth slows down from recent single-digit gains to nearly flat performance as increased pharmacy regulation and rising patient healthcare costs squeeze overall company profits.
Base case, $621.21
This scenario envisions steady mid-single-digit sales gains in line with recent quarterly performance, as robust demand for specialty medications balances higher medical claims and maintains stable profitability.
Bull case, $929.66
This scenario envisions strong performance where rapid adoption of high-value specialty drugs and market share wins in commercial health plans drive faster revenue gains and expanding profits.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects less than we do.Margin of safety: 52%
At today's $300.16, the price makes sense if sales shrink about 8.2% a year. We assume they grow 4.5%. Over the last 5 years, sales grew 11.0% a year.
Or, if sales grow 4.5% as we assume, the price works with a profit margin of 1.9% (we assume 3.5%).
Keep in mind: a low price can mean investors see a risk that isn't in the filings yet. Check the Full research tab for what could go wrong.
Do you think sales will shrink?
Try your own numbersWe're moderately sure of this range: it scores 57 out of 100 on our checks. The weakest point is historical stability.
Test the assumptions
Our base value of $621.21 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average4.5%
- Operating margin3.5%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$621.21 107.0%


